PARP1 and Miyoshi myopathy: Similar to previous studies, we observed that the combination between decitabine and the HDACi JNJ-585 had synergistic anti-MM effects which were associated with enhanced caspase, PARP-1 and MCL-1 cleavage compared to either agent alone [25-28, 49].